Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 8/20 | 0.43 |
| ▸ | PPARG | P37231 | 7/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.41 |
| ▸ | CTSS | P25774 | 4/20 | 0.41 |
| ▸ | CTSK | P43235 | 3/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.39 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11349136 | 1.00 | ACE (0.47) | ACEITGB3ITGA2BPPARAPPARG | |
| SCHEMBL11346506 | 0.80 | ACE (0.46) | ACEITGB3ITGA2BPPARAPPARG | |
| SCHEMBL16119290 | 0.78 | ACE (0.48) | ACEITGB3ITGA2BPPARAPPARG | |
| SCHEMBL16228847 | 0.78 | ACE (0.48) | ACEITGB3ITGA2BPPARAPPARG | |
| SCHEMBL12940447 | 0.77 | ACE (0.47) | ACEITGB3ITGA2BPPARAPPARG | |
| SCHEMBL10808779 | 0.76 | LMNA (0.44) | ACEPPARAPPARGPPARDCTSS | |
| SCHEMBL27846457 | 0.76 | LMNA (0.44) | ACEPPARAPPARGPPARDCTSS | |
| SCHEMBL14118068 | 0.75 | ACE (0.48) | ACEITGB3ITGA2BPPARAPPARG | |
| SCHEMBL15367523 | 0.74 | ACE (0.47) | ACEITGB3ITGA2BPPARAPPARG | |
| SCHEMBL21875826 | 0.74 | ACE (0.45) | ACEITGB3ITGA2BPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421178-B2 | Non-cryogenic, ammonia-free reduction of aryl compounds | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-09-23 | — | — | US | disclosed |
| US-20240092708-A1 | Non-Cryogenic, Ammonia-Free Reduction of Aryl Compounds | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2024-03-21 | — | — | US | disclosed |
| US-11866386-B2 | Non-cryogenic, ammonia-free reduction of aryl compounds | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2024-01-09 | — | — | US | disclosed |
| US-20220089508-A1 | Non-Cryogenic, Ammonia-Free Reduction of Aryl Compounds | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092708-A1 | Non-Cryogenic, Ammonia-Free Reduction of Aryl Compounds | NAT1, AADAC, ARNT | ACE 976/4885ITGB3 4442/4885ITGA2B 3947/4885 |
| US-12421178-B2 | Non-cryogenic, ammonia-free reduction of aryl compounds | NAT1, AADAC, ARNT | ACE 976/4885ITGB3 4442/4885ITGA2B 3947/4885 |
| US-20220089508-A1 | Non-Cryogenic, Ammonia-Free Reduction of Aryl Compounds | NAT1, AADAC, ARNT | ACE 976/4885ITGB3 4442/4885ITGA2B 3947/4885 |
| US-11866386-B2 | Non-cryogenic, ammonia-free reduction of aryl compounds | NAT1, AADAC, ARNT | ACE 976/4885ITGB3 4442/4885ITGA2B 3947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.